Free Newsletter
Lonza board boots CEO Borgas
Pressure from Asian low-cost chemical and drug ingredient suppliers, combined with high Swiss energy costs impacting manufacturing operations, have yielded poor financial performance at Lonza and the ouster of CEO Stefan Borgas. "Our decision to replace Borgas was made during the past 48 hours and is backed by the board and management," said board chairman and acting-CEO Rolf Soiron. Story
More stories about Lonza
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: